环硅酸锆钠
Sodium Zirconium Cyclosilicate.
作者信息
Levien Terri L, Baker Danial E
机构信息
Washington State University, Spokane, USA.
出版信息
Hosp Pharm. 2019 Feb;54(1):12-19. doi: 10.1177/0018578718817470. Epub 2018 Dec 14.
Abstract
Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about , contact Wolters Kluwer customer service at 866-397-3433.
摘要
每月，订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的资料详实的专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到关于对议程以及药房/护理在职培训有用药物的1页摘要专题论文。每月还会提供一份全面的目标药物利用评估/用药评估（DUE/MUE）。订阅后，专题论文可供订阅者在线获取。专题论文可进行定制以满足机构的需求。通过合作，出版方会在本专栏发表精选评论。如需了解更多关于……的信息，请致电866 - 397 - 3433联系威科集团客服。
相似文献
1
Sodium Zirconium Cyclosilicate.环硅酸锆钠
Hosp Pharm. 2019 Feb;54(1):12-19. doi: 10.1177/0018578718817470. Epub 2018 Dec 14.
2
Formulary Drug Review: Edaravone.处方药物审查：依达拉奉
Hosp Pharm. 2017 Dec;52(11):732-736. doi: 10.1177/0018578717734877. Epub 2017 Oct 9.
3
Formulary Drug Review: Ocrelizumab.处方药物评审：奥瑞珠单抗
Hosp Pharm. 2017 Oct;52(9):599-606. doi: 10.1177/0018578717731733. Epub 2017 Sep 17.
4
Angiotensin II.血管紧张素II
Hosp Pharm. 2018 Jul;53(4):230-233. doi: 10.1177/0018578718778224. Epub 2018 May 24.
5
Formulary Drug Review: Betrixaban.处方药物审查：贝曲西班
Hosp Pharm. 2018 Feb;53(1):29-37. doi: 10.1177/0018578717739397. Epub 2017 Nov 6.
6
Formulary Drug Review: Sufentanil Sublingual.处方药物评审：舒芬太尼舌下给药制剂
Hosp Pharm. 2019 Aug;54(4):222-228. doi: 10.1177/0018578719851726. Epub 2019 May 29.
7
Omadacycline.奥马环素
Hosp Pharm. 2019 Apr;54(2):80-87. doi: 10.1177/0018578718823730. Epub 2019 Jan 22.
8
Zoster Vaccine Recombinant, Adjuvanted.重组带状疱疹疫苗，含佐剂。
Hosp Pharm. 2018 Jun;53(3):136-141. doi: 10.1177/0018578718767103. Epub 2018 Apr 2.
9
Sugammadex.舒更葡糖钠
Hosp Pharm. 2016 Jul;51(7):585-96. doi: 10.1310/hpj5107-585.
10
Insulin Degludec/Liraglutide.德谷胰岛素/利拉鲁肽
Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1.
引用本文的文献
1
EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure.EMCREG - 慢性肾脏病和心力衰竭高钾血症管理国际多学科共识小组
Cardiorenal Med. 2025;15(1):133-152. doi: 10.1159/000543385. Epub 2025 Jan 14.
2
Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.高钾血症的管理：科威特专家共识——一种改良的德尔菲法
Int J Nephrol Renovasc Dis. 2024 Oct 5;17:227-240. doi: 10.2147/IJNRD.S476344. eCollection 2024.
3
Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.环硅酸锆钠治疗慢性肾脏病 4-5 期且透析的儿童急性和慢性高钾血症的安全性和疗效。
Pediatr Nephrol. 2024 Apr;39(4):1213-1219. doi: 10.1007/s00467-023-06176-6. Epub 2023 Oct 20.
4
Hyperkalemia in CKD: an overview of available therapeutic strategies.慢性肾脏病中的高钾血症：现有治疗策略概述
Front Med (Lausanne). 2023 Jul 31;10:1178140. doi: 10.3389/fmed.2023.1178140. eCollection 2023.
5
New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease.慢性肾脏病患者高钾血症的新治疗选择
J Clin Med. 2020 Jul 22;9(8):2337. doi: 10.3390/jcm9082337.
本文引用的文献
1
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.心力衰竭患者使用环硅锆酸钠（ZS-9）维持血清钾水平：一项3期随机、双盲、安慰剂对照试验的结果
Eur J Heart Fail. 2015 Oct;17(10):1050-6. doi: 10.1002/ejhf.300. Epub 2015 Jun 16.
2
Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia.环硅酸锆钠用于严重高钾血症的紧急治疗。
N Engl J Med. 2015 Apr 16;372(16):1577-8. doi: 10.1056/NEJMc1500353.
3
Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate.高钾血症与聚苯乙烯磺酸钠的潜在陷阱
JAAPA. 2015 Mar;28(3):41-5. doi: 10.1097/01.JAA.0000458856.92020.1e.
4
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.一项针对慢性肾病患者高钾血症治疗的2期研究表明，选择性钾离子捕获剂ZS-9安全且有效。
Kidney Int. 2015 Aug;88(2):404-11. doi: 10.1038/ki.2014.382. Epub 2015 Feb 4.
5
Characterization of structure and function of ZS-9, a K+ selective ion trap.钾离子选择性离子阱ZS-9的结构与功能表征
PLoS One. 2014 Dec 22;9(12):e114686. doi: 10.1371/journal.pone.0114686. eCollection 2014.
6
Sodium zirconium cyclosilicate in hyperkalemia.硅酸锆钠治疗高钾血症。
N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21.
7
A new era for the treatment of hyperkalemia?高钾血症治疗的新时代？
N Engl J Med. 2015 Jan 15;372(3):275-7. doi: 10.1056/NEJMe1414112. Epub 2014 Nov 21.
8
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.在接受 RAAS 抑制剂治疗的肾病和高钾血症患者中应用帕替络尔。
N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.
9
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.环硅酸锆钠降低高钾血症门诊患者血钾水平 28 天的疗效：HARMONIZE 随机临床试验。
JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688.
10
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.评价聚合物钾结合剂 RLY5016 在慢性心力衰竭（PEARL-HF 试验）患者中进行的双盲、安慰剂对照研究中的疗效和安全性。
Eur Heart J. 2011 Apr;32(7):820-8. doi: 10.1093/eurheartj/ehq502. Epub 2011 Jan 5.
Zotero 插件